Alnylam Near 52-Week Low With Amvuttra in Focus
Alnylam Pharmaceuticals dropped 2.16% to finish Monday at $295.47, and was just above that level in after-hours action. The Cambridge, Massachusetts biotech is sitting about 4% above its 52-week low, down about 40% from an October high. Shares moved in a $295.14 to $303.98 range for the day. The market lost ground on that news. U.S. stocks were mostly higher, with Reuters saying the S&P 500 was up 0.43% and the Nasdaq up 0.69% as tech names gained. Only technology and energy were in the green out of the 11 S&P sectors. Alnylam’s story is different, though—a heart-drug stock that’s still stuck at the low end of its one-year range.